Hyperpolarized 129Xe

Phase 2Small molecule

Hyperpolarized 129Xe is one of 140 small molecule programs targeting Pulmonary Hypertension. It is currently in Phase 2.

Indications

Total Trials

Active Trials

139

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary HypertensionActive, not recruiting

Interstitial Lung DiseaseActive, not recruiting

COVID-19Active, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Pulmonary HypertensionPhase 2

Active, not recruiting

Interstitial Lung DiseasePhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Hyperpolarized 129Xe

BBastiaan Driehuys

Phase 2

1 2

Biaxin

AbbVie

Preclinical

2 3

Stivarga

Bayer

Preclinical

1 4

Aimovig

Amgen

Preclinical

1 5

Singulair

AstraZeneca

Preclinical

1 6

Activella

Eli Lilly

Preclinical

—7

Nitrostat

VViatris Specialty LLC

Preclinical

1 8

Rayaldee

OOrganon and Co

Preclinical

1 9

SARS-COV-2 VACCINE

Moderna

Preclinical

2 10

Statins

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Pulmonary Hypertension

NCT04778046

Q4 2030

Phase 2Recruiting

Pulmonary Function

NCT01280994

Clinical

Trials by Indication[1]

Pulmonary Function2 trials

Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment

Completed·BBastiaan Driehuys·Phase 2·NCT02478255·25 enrolled

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

Recruiting·BBastiaan Driehuys·Phase 2·NCT01280994·445 enrolled

Pulmonary Hypertension1 trial

Pulmonary Hypertension SOLAR

Recruiting·BBastiaan Driehuys·Phase 2·NCT04778046·30 enrolled

Interstitial Lung Disease1 trial

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Completed·BBastiaan Driehuys·Phase 2·NCT04855305·46 enrolled

ESS1 trial

Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI

Completed·BBastiaan Driehuys·Phase 2·NCT03367312·11 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

Completed·BBastiaan Driehuys·Phase 1·NCT02478268·64 enrolled

2 more indications

Ventilation1 trial

Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

Completed·BBastiaan Driehuys·Phase 2/3·NCT03324607·20 enrolled

COVID-191 trial

Dual MRI for Cardiopulmonary COVID-19 Long Haulers

Completed·BBastiaan Driehuys·Phase 2·NCT04828135·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Hyperpolarized 129Xe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized 129Xe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized 129Xe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bastiaan Driehuys company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBastiaan Driehuys

Hyperpolarized 129Xe

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2030

Trials by Indication[1]

Pulmonary Function2 trials

Pulmonary Hypertension1 trial

Interstitial Lung Disease1 trial

ESS1 trial

Idiopathic Pulmonary Fibrosis1 trial

Ventilation1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News